Zand V, Dadgarnia M, Baradaranfar M, Meybodian M, Vaziribozorg S, Fazilati M. The association between metabolic syndrome and the prognosis of idiopathic sudden sensorineural hearing loss.
Eur Arch Otorhinolaryngol 2023;
280:1411-1415. [PMID:
36210371 DOI:
10.1007/s00405-022-07686-z]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2022] [Accepted: 10/01/2022] [Indexed: 02/07/2023]
Abstract
INTRODUCTION
In this study, we investigated the association between metabolic syndrome and the prognosis of idiopathic sudden sensorineural hearing loss.
METHODS
In this prospective cohort study, 79 patients with idiopathic SSNHL admitted to the ENT ward were involved. Patients were under treatment with two-dose pulse methylprednisolone and then oral corticosteroid (Prednisolone 1 mg/kg for up to 2 weeks and more). In all patients, the mean hearing threshold was measured before treatment and 3 weeks after the treatment. Metabolic syndrome criteria were assessed in all patients too. Then, based on these diagnostic criteria all data in patients with and without metabolic were compared.
RESULTS
There was a significant difference in Hypertension, BMI > 25, high TG and low HDL (p.v = 0.001) between two groups (metabolic syndrome group and non-metabolic syndrome group). The rate of recovered patients was significantly lower in the metabolic syndrome group than in the non-metabolic syndrome group (p.v = 0.001). It was found that metabolic syndrome (OR = 2.02), diabetes mellitus (OR = 7.32), HTN (OR = 4.09), BMI > 25 (OR = 3.24) and high initial hearing threshold (OR = 3.96) were clearly related to the poor prognosis of treatment.
CONCLUSIONS
According to the findings of this study, it was found that metabolic syndrome had a negative effect on hearing improvement in patients with idiopathic SSNHL.
Collapse